Notícias e Atividades da NewAmsterdam Pharma
Presença
NewAmsterdam Pharma é uma empresa listada sob o símbolo NAMS (NL).
Executivos
Veja o organograma con seus 27 executivos principais
Biografias mais buscadas da NewAmsterdam Pharma
- Michael Davidson, Chief Executive Officer and Director
- Janneke Van Der Kamp, Director
- Nicholas Downing, Director
Recentes movimentos de executivos em NewAmsterdam Pharma
- Adele Gulfo, ingressou na Companhia como Independent Director (Notícia publicada em 22 de abril de 2025).
- Jennifer Panagos, ingressou na Companhia como Head of Talent Acquisition (Notícia publicada em 21 de março de 2025).
Criar um alerta
para seguir os movimentos de executivos da NewAmsterdam Pharma.
Farmacêutica
NewAmsterdam Pharma possui 1.828 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).
Popular M&A news in Farmacêutica
- Chimerix and Chimerix have merged (publicado em 22 de abril de 2025)..
- Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
- Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de NewAmsterdam Pharma
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease | NewAmsterdam Pharma Company
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients | NewAmsterdam Pharma Company N.V.
- View more press releases Close
Redes sociais sobre NewAmsterdam Pharma
- NewAmsterdam Pharma na Wikipedia, Google News e Yahoo Finance
- NewAmsterdam Pharma na LinkedIn, Twitter e YouTube
